|Mr. Larry G. Edwards||Pres, CEO & Director||749.17k||N/A||1972|
|Mr. Michael S. Hearne||CFO & Sec.||186.04k||N/A||1963|
|Dr. Lakhmir S. Chawla||Consultant||478.97k||N/A||1971|
|Ms. Paula Rusu||VP of Operations||N/A||N/A||N/A|
|Ms. Sandra Vedrick||Sr. Director of Investor Relations & HR||N/A||N/A||N/A|
|Mr. Thomas Ouellette||VP of Sales & Marketing||N/A||N/A||N/A|
|Mr. Luke Seikkula||Sr. VP of Pharmaceutical Operations||N/A||N/A||1964|
|Mr. Stewart M. Kroll||Chief Devel. Officer||N/A||N/A||1959|
|Mr. Mark D. Williams||Sr. VP of Medical Affairs||N/A||N/A||N/A|
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.
La Jolla Pharmaceutical Company’s ISS Governance QualityScore as of July 1, 2021 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 2; Compensation: 9.